ZYME Financials: Zymeworks Inc AI Analysis



Financials

ZYME Financial

Zymeworks Inc

$27.94

-2.17%

$-0.61

At close: Apr 28, 16:00:00 GMT-4

$28.2

0.93%

$0.25

Post-market: Apr 28, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$28.56

Open

$28.61

Day's Range

$27.92 - $28.88

52 week range

$10.69 - $28.49

Volume

394.9K

Avg.Volume

710.1K

Dividend yield

EPS (TTM)

-1.77

Market Cap

$2.0B

What is ZYME?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 280 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ZYME Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	105	2	27	48	27	31
Revenue Growth (YoY)	38%	-94%	69%	153%	170%	94%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	61	15	14	14	16	16
Research & Development	137	31	35	34	35	37
Operating Expenses	198	46	49	49	52	53
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-79	-41	-18	2	-22	-17
Income Tax Expense	1	0	1	0	0	5
Net Income	-81	-41	-19	2	-22	-23
Net Income Growth	-34%	78%	-34%	-105%	-31%	64%
Shares Outstanding (Diluted)	75.33	75.33	75.76	77.37	75.17	74.65
Shares Change (YoY)	1%	1%	0%	2%	-1%	5%
EPS (Diluted)	-1.07	-0.54	-0.25	0.02	-0.3	-0.31
EPS Growth	-35%	74%	-34%	-106%	-28%	54%
Free Cash Flow	-35	-10	-31	11	-3	-41
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-87.61%	-2,200%	-81.48%	0%	-92.59%	-70.96%
Profit Margin	-77.14%	-2,050%	-70.37%	4.16%	-81.48%	-74.19%
Free Cash Flow Margin	-33.33%	-500%	-114.81%	22.91%	-11.11%	-132.25%
EBITDA	-85	-43	-21	2	-23	-21
EBITDA Margin	-80.95%	-2,150%	-77.77%	4.16%	-85.18%	-67.74%
D&A For EBITDA	7	1	1	2	2	1
EBIT	-92	-44	-22	0	-25	-22
EBIT Margin	-87.61%	-2,200%	-81.48%	0%	-92.59%	-70.96%
Effective Tax Rate	-1.26%	0%	-5.55%	0%	0%	-29.41%

Follow-Up Questions

What are Zymeworks Inc's key financial statements?



According to the latest financial statement (Form-10K), Zymeworks Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ZYME?



Zymeworks Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Zymeworks Inc's revenue broken down by segment or geography?



Zymeworks Inc largest revenue segment is License and Development Support, at a revenue of 251,000 in the most earnings release.For geography, United States is the primary market for Zymeworks Inc, at a revenue of 251,000.

Is Zymeworks Inc profitable?



no, according to the latest financial statements, Zymeworks Inc has a net loss of $0

Does Zymeworks Inc have any liabilities?



no, Zymeworks Inc has liability of 0

How many outstanding shares for Zymeworks Inc?



Zymeworks Inc has a total outstanding shares of 0

Zymeworks Inc (ZYME) Financial

ZYME Stock Price Chart